Title: Toluene exposure enhances acute and chronic formalin-induced nociception in rats: Participation of 5-HT(3) receptors.
Journal: Neurotoxicology 20171201
Title: Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Journal: Expert opinion on pharmacotherapy 20150101
Title: 'Pre-cebo': an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials.
Journal: Journal of clinical gastroenterology 20120901
Title: Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
Journal: Alimentary pharmacology & therapeutics 20120901
Title: Experimental colitis alters expression of 5-HT receptors and transient receptor potential vanilloid 1 leading to visceral hypersensitivity in mice.
Journal: Laboratory investigation; a journal of technical methods and pathology 20120501
Title: Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Journal: The American journal of medicine 20120401
Title: Evaluation of treatment continuation with alosetron by IBS-D severity criteria.
Journal: Current medical research and opinion 20120301
Title: Quality of life in patients with irritable bowel syndrome.
Journal: Journal of clinical gastroenterology 20110801
Title: The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Journal: Drug safety 20110701
Title: Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Journal: Current medical research and opinion 20110301
Title: Peripherally acting therapies for the treatment of irritable bowel syndrome.
Journal: Gastroenterology clinics of North America 20110301
Title: An electrochemical microfluidic platform for human P450 drug metabolism profiling.
Journal: Analytical chemistry 20101215
Title: In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
Journal: Journal of chemical information and modeling 20100726
Title: Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
Journal: The American journal of gastroenterology 20100401
Title: Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Journal: Expert review of gastroenterology & hepatology 20100201
Title: Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101
Title: Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101
Title: Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.
Journal: British journal of pharmacology 20091101
Title: Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Journal: The American journal of gastroenterology 20090701
Title: Intracolonical administration of protease-activated receptor-2 agonists produced visceral hyperalgesia by up-regulating serotonin in the colon of rats.
Journal: European journal of pharmacology 20090315
Title: Pathogenesis and management of irritable bowel syndrome.
Journal: Tropical gastroenterology : official journal of the Digestive Diseases Foundation 20090101
Title: Increased 5-hydroxytryptamine mediates post-inflammatory visceral hypersensitivity via the 5-hydroxytryptamine 3 receptor in rats.
Journal: Digestive diseases and sciences 20081101
Title: Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study.
Journal: Alimentary pharmacology & therapeutics 20080801
Title: Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.
Journal: European journal of pharmacology 20080610
Title: Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20080501
Title: Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Journal: Clinical therapeutics 20080501
Title: Clinical practice. Irritable bowel syndrome.
Journal: The New England journal of medicine 20080417
Title: Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
Journal: The American journal of gastroenterology 20080401
Title: Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
Journal: European journal of pharmacology 20071114
Title: A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Journal: The American journal of gastroenterology 20070801
Title: Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070801
Title: The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20070801
Title: The metabolism of the 5HT3 antagonists, ondansetron, alosetron and GR87442 II: investigation into the in vitro methods used to predict the in vivo hepatic clearance of ondansetron, alosetron and GR87442 in the rat, dog and human.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20070801
Title: Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia.
Journal: Pain 20070701
Title: Impact of 5-HT3 receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat.
Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070701
Title: Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
Journal: Journal of pharmacological sciences 20070701
Title: [Novel therapeutic approaches in the treatment of irritable bowel syndrome].
Journal: Orvosi hetilap 20070520
Title: [Drug treatment of irritable bowel syndrome: an unmet need].
Journal: Gastroenterologia y hepatologia 20070301
Title: The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme.
Journal: Alimentary pharmacology & therapeutics 20070201
Title: Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?
Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070201
Title: Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia.
Journal: Pain 20061215
Title: Irritable bowel syndrome: a practical review.
Journal: Southern medical journal 20061101
Title: A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme.
Journal: Alimentary pharmacology & therapeutics 20060901
Title: [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20060801
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Title: Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
Journal: The American journal of gastroenterology 20060501
Title: Alosetron: ischemic colitis and serious complications of constipation.
Journal: The American journal of gastroenterology 20060501
Title: Drug withdrawals and the lessons within.
Journal: Current opinion in drug discovery & development 20060101
Title: Acute hepatitis associated with alosetron (Lotronex).
Journal: Journal of clinical gastroenterology 20050801
Title: Novelty stress increases fecal pellet output in mongolian gerbils: effects of several drugs.
Journal: Journal of pharmacological sciences 20050801
Title: Intestinal propulsion of a solid non-deformable bolus.
Journal: Journal of theoretical biology 20050707
Title: Pharmacogenomics and functional gastrointestinal disorders.
Journal: Pharmacogenomics 20050701
Title: The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20050401
Title: Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20050401
Title: Characterization of the metabolites of alosetron in experimental animals and human.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20050201
Title: A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Journal: The American journal of gastroenterology 20050101
Title: Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis.
Journal: Geriatrics 20050101
Title: [Irritable bowel syndrome: a concise diagnostic and pharmacological therapy review].
Journal: Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 20050101
Title: Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20041201
Title: Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Journal: The American journal of gastroenterology 20041101
Title: Delayed Gastric Emptying in Functional Dyspepsia.
Journal: Current treatment options in gastroenterology 20040801
Title: Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20040801
Title: Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).
Journal: Digestive diseases and sciences 20040801
Title: Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.
Journal: Alimentary pharmacology & therapeutics 20040715
Title: Alosetron use drops dramatically with risk management.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040615
Title: Advances in pharmacological treatments of IBS.
Journal: Journal of pediatric gastroenterology and nutrition 20040601
Title: Irritable bowel syndrome.
Journal: Clinical evidence 20040601
Title: New drugs and dosage forms.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040415
Title: Therapy for irritable bowel syndrome.
Journal: The New England journal of medicine 20040318
Title: New options for soothing an irritable bowel.
Journal: The Johns Hopkins medical letter health after 50 20040301
Title: Study design issues in irritable bowel syndrome.
Journal: Alimentary pharmacology & therapeutics 20040101
Title: 5-HT3-receptor antagonist inhibits visceral pain differently in chemical and mechanical stimuli in rats.
Journal: Journal of pharmacological sciences 20040101
Title: Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
Journal: Drug safety 20040101
Title: Advances in the management of irritable bowel syndrome.
Journal: Current gastroenterology reports 20031201
Title: Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
Journal: The American journal of gastroenterology 20031201
Title: Alosetron and irritable bowel syndrome.
Journal: Expert opinion on pharmacotherapy 20031101
Title: Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
Journal: The American journal of gastroenterology 20030901
Title: Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.
Journal: Cleveland Clinic journal of medicine 20030601
Title: Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
Journal: The American journal of gastroenterology 20030501
Title: Regulatory role of 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats.
Journal: European journal of pharmacology 20030425
Title: Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications.
Journal: Alimentary pharmacology & therapeutics 20030401
Title: Bad medicine. Why data from drug companies may be hard to swallow.
Journal: Scientific American 20030201
Title: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20030201
Title: Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.
Journal: BMJ (Clinical research ed.) 20030104
Title: Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
Journal: BMJ (Clinical research ed.) 20030104
Title: Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
Journal: Alimentary pharmacology & therapeutics 20030101
Title: Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?
Journal: Cleveland Clinic journal of medicine 20030101
Title: Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response.
Journal: The pharmacogenomics journal 20030101
Title: Tegaserod and other serotonergic agents: what is the evidence?
Journal: Reviews in gastroenterological disorders 20030101
Title: Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
Journal: Drugs 20030101
Title: Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Journal: The American journal of gastroenterology 20021201
Title: Evidence-based position statement on the management of irritable bowel syndrome in North America.
Journal: The American journal of gastroenterology 20021101
Title: Systematic review on the management of irritable bowel syndrome in North America.
Journal: The American journal of gastroenterology 20021101
Title: New developments in the diagnosis and treatment of irritable bowel syndrome.
Journal: Current gastroenterology reports 20021001
Title: Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
Journal: Gastroenterology 20021001
Title: FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
Journal: Health news (Waltham, Mass.) 20021001
Title: Alosetron for irritable bowel syndrome.
Journal: BMJ (Clinical research ed.) 20020914
Title: FDA advisers warn of more deaths if drug is relaunched.
Journal: BMJ (Clinical research ed.) 20020914
Title: Alosetron: a case study in regulatory capture, or a victory for patients' rights?
Journal: BMJ (Clinical research ed.) 20020914
Title: From the Food and Drug Administration.
Journal: JAMA 20020814
Title: Alosetron (lotronex) revisited.
Journal: The Medical letter on drugs and therapeutics 20020805
Title: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.
Journal: Gastroenterology 20020801
Title: Contemporary thoughts on the treatment of irritable bowel syndrome.
Journal: Managed care interface 20020801
Title: Alosetron to return to market.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020715
Title: The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Journal: Alimentary pharmacology & therapeutics 20020701
Title: FDA allows controversial bowel drug back on to market.
Journal: Lancet (London, England) 20020615
Title: FDA advisory panels recommend Lotronex be put back on market.
Journal: BMJ (Clinical research ed.) 20020504
Title: Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Journal: Alimentary pharmacology & therapeutics 20020501
Title: Return of alosetron.
Journal: Expert opinion on drug safety 20020501
Title: FDA recommends bringing controversial IBS drug back.
Journal: Lancet (London, England) 20020427
Title: Sex and age differences in the pharmacokinetics of alosetron.
Journal: British journal of clinical pharmacology 20020301
Title: Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans.
Journal: Alimentary pharmacology & therapeutics 20020201
Title: Safety concerns about alosetron.
Journal: Archives of internal medicine 20020114
Title: Lotronex withdrawal.
Journal: Archives of internal medicine 20020114
Title: FDA approves restricted marketing of Lotronex.
Journal: FDA consumer 20020101
Title: Adverse drug reaction update.
Journal: Adverse drug reactions and toxicological reviews 20020101
Title: Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Journal: The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 20020101
Title: Serotoninergic neuroenteric modulators.
Journal: Lancet (London, England) 20011215
Title: Effect of alosetron on theophylline pharmacokinetics.
Journal: British journal of clinical pharmacology 20011101
Title: Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
Journal: American journal of physiology. Gastrointestinal and liver physiology 20011001
Title: [Irritable bowel syndrome: diagnostic criteria and recent advancement of its pharmacological management].
Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20011001
Title: Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Journal: The American journal of gastroenterology 20010901
Title: Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
Journal: The American journal of gastroenterology 20010901
Title: [Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives].
Journal: Gastroenterologie clinique et biologique 20010901
Title: [Functional intestinal disorders and quality of life].
Journal: Gastroenterologie clinique et biologique 20010901
Title: The FDA and The Lancet: an exchange.
Journal: Lancet (London, England) 20010804
Title: The FDA and The Lancet: an exchange.
Journal: Lancet (London, England) 20010804
Title: The FDA and The Lancet: an exchange.
Journal: Lancet (London, England) 20010804
Title: The FDA and The Lancet: an exchange.
Journal: Lancet (London, England) 20010804
Title: The FDA and The Lancet: an exchange.
Journal: Lancet (London, England) 20010804
Title: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Journal: Archives of internal medicine 20010723
Title: Possible mechanisms for ischemic colitis during alosetron therapy.
Journal: Gastroenterology 20010701
Title: Lotronex and the FDA: a fatal erosion of integrity.
Journal: Lancet (London, England) 20010519
Title: Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.
Journal: Gut 20010501
Title: So what happened to alosetron?
Journal: Journal of pediatric gastroenterology and nutrition 20010501
Title: [Irritable bowel syndrome as an interdisciplinary clinical challenge. Current views on its pathophysiology, diagnosis and treatment].
Journal: Deutsche medizinische Wochenschrift (1946) 20010420
Title: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
Journal: Alimentary pharmacology & therapeutics 20010401
Title: Effect of alosetron on the pharmacokinetics of alprazolam.
Journal: Journal of clinical pharmacology 20010401
Title: Effect of alosetron on the pharmacokinetics of fluoxetine.
Journal: Journal of clinical pharmacology 20010401
Title: The challenge of irritable bowel syndrome: creating an alliance between patient and physician.
Journal: Cleveland Clinic journal of medicine 20010301
Title: Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
Journal: The American journal of gastroenterology 20010301
Title: Alosetron and the rapid component of delayed rectifying potassium current in cardiac cells.
Journal: Life sciences 20010223
Title: Ischemic colitis during treatment with alosetron.
Journal: Gastroenterology 20010201
Title: Lotronex withdrawn from market.
Journal: Harvard women's health watch 20010201
Title: Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
Journal: The American journal of gastroenterology 20010201
Title: Alosetron withdrawn from market.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010101
Title: Novel medications for the irritable bowel syndrome: motility and sensation.
Journal: Journal of pediatric gastroenterology and nutrition 20010101
Title: Irritable bowel syndrome. A poorly understood disorder.
Journal: FDA consumer 20010101
Title: Glaxo Wellcome withdraws irritable bowel syndrome medication.
Journal: FDA consumer 20010101
Title: Pharmacology and clinical experience with alosetron.
Journal: Expert opinion on investigational drugs 20000101
Title: Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome By Spiller, Robin C. From Current Opinion in Pharmacology (2011), 11(1), 68-74.
Title: Lucak SL.Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.Therap Adv Gastroenterol. 2010 May;3(3):165-72.
Title: Lewis JH.Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):13-29.
Title: Turgeon DK, Tayeh N, Fontana RJ.Acute hepatitis associated with alosetron (Lotronex).J Clin Gastroenterol. 2005 Aug;39(7):641-2.
Title: Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM.Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.Am J Gastroenterol. 2003 May;98(5):1117-22.
Title: Balfour JA, Goa KL, Perry CM. Alosetron. Drugs. 2000;59(3):511-520.
Title: Motavallian A, et al. Anti-inflammatory effects of alosetron mediated through 5-HT3 receptors on experimental colitis. Res Pharm Sci. 2019;14(3):228-236.
